

Minutes from Scandinavian Sarcoma Group`s TC board meeting 2017-12-12.

Time 16.00 -16.40

Attendees

Kirsten Sundby Hall

Eva-Mari Olofsson (meeting secretary)

Mikael Eriksson from Paragraph 6

Thomas Baad-Hansen

Fredrik Mertens

Hans Kristian Haugland

1.

Approval of minutes from the last board meeting

Minutes for the board meeting held at Scandic Aarhus City Hotel, in connection with the 38th Plenary meeting of the Scandinavian Sarcoma Group in Aarhus on 2017-09-19, was approved.

2.

Economy

Fredrik Mertens, treasurer, gave a report of the economic status of SSG with a focus on the recent 38th Plenary meeting of the Scandinavian Sarcoma Group in Aarhus.

The plenary meeting seems to be financially balanced. There are still some remaining costs due to reimbursement to invited speakers and lack of payment of registration fee from 7 participants. On request sponsors can have access to the final budget. Currently the equity of SSG is per December 2017: 2,875,818 SEK.

Expenses

-Salary, web hotel: 600,000 SEK/year

-office rent: estimated to 50,000/year

-SSG trials: SSG XVIII, SSG XX, SSG XXI, rEECur, STOP-GIST. Costs related to number of patients accrued. Monitoring etc by CROAK AB <400,000 SEK for 2017.

Income

SSG XXII: 210,000 USD in 2017; SSGXXI: 47,186 Euros in 2018?; ALT GIST: currently unsolved.

Summary:

Aarhus meeting financed and the budget is in balance for 2018. However, new sources of income are needed and the topic will be addressed at the next WGN in January 2018.

3.

Working Group Meeting, Malmö, 22-23, January, 2018

The program for the different subgroups meeting seems to in place, however there have been some overrun of the deadline which makes it difficult to organize the WGM. The board members will action on the issue in the relevant subgroups.

The program for the WGM is in place and can be seen at

http://www.ssg-org.net/wp-content/uploads/2017/10/EMO_28.11.2017-Program-hafte_Arbetsm22_Malmo2018.pdf

There will be extra attention on the form of the future meetings in SSG and will be discussed separately.

4.

Pathology/Morphology subcommittee: status

This issue was again discussed, as mentioned at the last board meeting Kirsten has been in contact with the former chairman of the group, Bodil Bjerkehagen, however there is no solution for the activities of the Pathology/Morphology subcommittee. Our hopes are that a new chairman will be found at the next WGM in Malmö. To kick start the group it was suggested to initiate a study leading to systematic measurement of histological response after preoperative chemotherapy or radiotherapy.

5.

Plenary meeting Bergen 2019: status

The work is in progress. In one of the next days the local committee in Bergen will meet. The committee will create a “concept” plan, which may be presented at the WGM? It was agreed that the concept plan should be approved before approaching potential sponsors. Kirsten will provide blueprints from earlier meeting so the group don't have to start from the beginning.

6.

Information by KSH: Osteosarcoma relapse: invitation to a register study

SSG has recently been contacted by Maj van de Sande from the Leiden University Hospital, the Netherlands. His group and Koichi Ogura (orthopedic surgeon currently working at MSKCC) have proposed to collaborate with us on a new project to determine survival of patients with lung mets in osteosarcoma patients. Unfortunately, SSG already participates in a similar study, the Eurelos study. Kirsten has respectfully declined to participate on behalf of the Norwegian sarcoma group since they already have sent data to the Eurelos study. This is however not the case for the Swedish, the Danish and the Finnish sarcoma group. Maj van de Sande is most welcome to contact Michael and Thomas in order to start a research collaboration with the national sarcoma groups. Kirsten will mail van der Sande upon that.

7.

ECT

N/A

Next board meeting (in connection to the next WGM in Malmö) Sunday, January 21st at 17:00-19.15, 2018.